Details for Prevenar 13 vaccine and its components.
Registered for use in children aged ≥6 weeks and in adults.
13vPCV — 13-valent pneumococcal conjugate vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- 2.2 µg each of pneumococcal capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F
- 4.4 µg of pneumococcal capsular polysaccharide of serotype 6B
- succinic acid
- polysorbate 80
Antigens are conjugated to non-toxic Corynebacterium diphtheriae CRM197 protein and adsorbed onto 0.565 mg aluminium phosphate.
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
- 13-valent pneumococcal conjugate vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/prevenar-13.